BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38594140)

  • 1. Unitary Tract Infection Treatment: When to Use What Agents including Beta-lactam Combination Agents.
    Yassin A; Kaye KS; Bhowmick T
    Infect Dis Clin North Am; 2024 Jun; 38(2):295-310. PubMed ID: 38594140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosing and Managing Urinary Tract Infections in Kidney Transplant Recipients.
    McAteer J; Tamma PD
    Infect Dis Clin North Am; 2024 Jun; 38(2):361-380. PubMed ID: 38729666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Childhood urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and empiric therapy.
    Uyar Aksu N; Ekinci Z; Dündar D; Baydemir C
    Pediatr Int; 2017 Feb; 59(2):176-180. PubMed ID: 27501161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
    Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing Carbapenem Exposure: Extended-Spectrum β-Lactamase Catheter-Associated Urinary Tract Infection Management.
    Holt S; Grant M; Thompson-Brazill KA
    Crit Care Nurse; 2017 Oct; 37(5):78-84. PubMed ID: 28966198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
    Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
    Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
    Yamamoto A; Yamasaki K
    Nihon Ronen Igakkai Zasshi; 2015; 52(2):153-61. PubMed ID: 25994987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
    BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
    Meier S; Weber R; Zbinden R; Ruef C; Hasse B
    Infection; 2011 Aug; 39(4):333-40. PubMed ID: 21706226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of urinary tract infections from multidrug-resistant organisms.
    Gupta K; Bhadelia N
    Infect Dis Clin North Am; 2014 Mar; 28(1):49-59. PubMed ID: 24484574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum beta-lactamase-producing bacteria and vesicoureteral reflux in children.
    Ito S; Machida H; Harada T; Teranishi J; Aihara Y; Yokota S
    Pediatr Int; 2010 Feb; 52(1):134-7. PubMed ID: 20158657
    [No Abstract]   [Full Text] [Related]  

  • 18. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Antibiotics in the Treatment of Urinary Tract Infections.
    Naber KG; Wagenlehner FME
    Eur Urol Focus; 2019 Jan; 5(1):10-12. PubMed ID: 30555037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
    Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
    Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.